Detalles de la búsqueda
1.
T cell-engaging BiTE antibodies specific for EGFR potently eliminate KRAS- and BRAF-mutated colorectal cancer cells.
Proc Natl Acad Sci U S A
; 107(28): 12605-10, 2010 Jul 13.
Artículo
en Inglés
| MEDLINE | ID: mdl-20616015
2.
Selective targeting and potent control of tumor growth using an EphA2/CD3-Bispecific single-chain antibody construct.
Cancer Res
; 67(8): 3927-35, 2007 Apr 15.
Artículo
en Inglés
| MEDLINE | ID: mdl-17440108
3.
MT110: a novel bispecific single-chain antibody construct with high efficacy in eradicating established tumors.
Mol Immunol
; 43(8): 1129-43, 2006 Mar.
Artículo
en Inglés
| MEDLINE | ID: mdl-16139892
4.
Eradication of tumors from a human colon cancer cell line and from ovarian cancer metastases in immunodeficient mice by a single-chain Ep-CAM-/CD3-bispecific antibody construct.
Cancer Res
; 65(7): 2882-9, 2005 Apr 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-15805290
5.
Regression of human prostate cancer xenografts in mice by AMG 212/BAY2010112, a novel PSMA/CD3-Bispecific BiTE antibody cross-reactive with non-human primate antigens.
Mol Cancer Ther
; 11(12): 2664-73, 2012 Dec.
Artículo
en Inglés
| MEDLINE | ID: mdl-23041545
6.
Targeted therapy with the T-cell-engaging antibody blinatumomab of chemotherapy-refractory minimal residual disease in B-lineage acute lymphoblastic leukemia patients results in high response rate and prolonged leukemia-free survival.
J Clin Oncol
; 29(18): 2493-8, 2011 Jun 20.
Artículo
en Inglés
| MEDLINE | ID: mdl-21576633
7.
Combination of rituximab with blinatumomab (MT103/MEDI-538), a T cell-engaging CD19-/CD3-bispecific antibody, for highly efficient lysis of human B lymphoma cells.
Leuk Res
; 33(3): 465-73, 2009 Mar.
Artículo
en Inglés
| MEDLINE | ID: mdl-18835037
8.
Potent control of tumor growth by CEA/CD3-bispecific single-chain antibody constructs that are not competitively inhibited by soluble CEA.
J Immunother
; 32(4): 341-52, 2009 May.
Artículo
en Inglés
| MEDLINE | ID: mdl-19342971
9.
Antitumor activity of an EpCAM/CD3-bispecific BiTE antibody during long-term treatment of mice in the absence of T-cell anergy and sustained cytokine release.
J Immunother
; 32(5): 452-64, 2009 Jun.
Artículo
en Inglés
| MEDLINE | ID: mdl-19609237
10.
Therapeutic window of MuS110, a single-chain antibody construct bispecific for murine EpCAM and murine CD3.
Cancer Res
; 68(1): 143-51, 2008 Jan 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-18172306
Resultados
1 -
10
de 10
1
Próxima >
>>